FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma. PMID 38437209 · PLoS One · 2024 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysis. PMID 38436076 · Expert Rev Anticancer Ther · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial. PMID 38410116 · Front Oncol · 2024 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial. PMID 38362377 · Ther Adv Med Oncol · 2024 The record describes a trial protocol (NCT05582499) without reported results. It is a prospective randomized umbrella trial with drug interventions and includes a time-to-event secondary endpoint (invasive disease-free survival), but the primary endpoint is pathological complete response, not a time-to-event efficacy endpoint. The phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata. Therefore, it does not meet all criteria for inclusion as an original result report of a definitive randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Novel model of pyroptosis-related molecular signatures for prognosis prediction of clear cell renal cell carcinoma patients. PMID 38250606 · Int J Med Sci · 2024 The record describes a retrospective bioinformatics study developing a prognostic model for ccRCC using public and institutional patient data. It does not meet the core eligibility criteria: it is not a randomized controlled trial (RCT) of a drug intervention with a primary/key secondary time-to-event efficacy endpoint from a Phase III/IIIb or Phase II/III study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer. PMID 38249330 · Ther Adv Med Oncol · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of volume computed tomography in lung cancer screening: a cohort simulation based on Nelson study outcomes. PMID 38050691 · J Med Econ · 2024 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A marginalized two-part joint model for a longitudinal biomarker and a terminal event with application to advanced head and neck cancers. PMID 37717945 · Pharm Stat · 2024 While the study is a randomized, human, oncology trial with a drug intervention and a time-to-event endpoint, the abstract's primary focus is on presenting a new statistical method (M-TPJM) applied to trial data. The explicit Phase (III/IIIb or II/III) is not confirmed in the provided metadata, and the report type is best classified as methodological rather than a primary formal-result report of efficacy, making it ineligible under the specified criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety of Procalcitonin Guided Early Discontinuation of Antibiotic Therapy among Children Receiving Cancer Chemotherapy and Having Low-Risk Febrile Neutropenia: A Randomized Feasibility Trial (ProFenC Study). PMID 37655541 · Pediatr Hematol Oncol · 2024 The study is a randomized trial in an oncology population with a drug intervention (antibiotics) and reports original results. However, it is a feasibility trial without a specified phase (likely early phase), and the primary/secondary endpoints are not time-to-event efficacy endpoints; they are treatment failure rates, antibiotic duration, and mortality counts without Kaplan-Meier analysis or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Predictive Modelling of Overall Survival in Adult Patients with Primary Diffuse Large B-cell Lymphoma of the Breast Using the Surveillance, Epidemiology, and End Results (SEER) Database. PMID 37464821 · Recent Pat Anticancer Drug Discov · 2024 The record is an observational prognostic modeling study using SEER database data, not a randomized controlled trial of a drug intervention. It lacks phase information and does not involve a drug-containing intervention or randomization, which are required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Influence of exogenous opioids on the acute inflammatory response in the perioperative period of oncological surgery: a clinical study. PMID 34624369 · Braz J Anesthesiol · 2024 The record describes a randomized controlled trial comparing anesthetic regimens in cancer surgery patients, measuring cytokine and oxidative stress biomarkers. While it meets the criteria for oncology, human, randomized, and drug intervention, it fails the key requirement for a primary or key secondary time-to-event efficacy endpoint. No Kaplan-Meier analysis, hazard ratio, or time-to-event data (e.g., OS, PFS) are reported. The phase is not definitively established as Phase II/III or III/IIIb. Therefore, it is not eligible for inclusion in this oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes. PMID 37836519 · Nutrients · 2023-Sep-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Overview, Diagnosis, and Perioperative Systemic Therapy of Upper Tract Urothelial Carcinoma. PMID 37835507 · Cancers (Basel) · 2023-Sep-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Development and testing of a random forest-based machine learning model for predicting events among breast cancer patients with a poor response to neoadjuvant chemotherapy. PMID 37777809 · Eur J Med Res · 2023-Sep-30 The record describes a machine learning model development study for predicting events in breast cancer patients after neoadjuvant chemotherapy, not a randomized clinical trial report. Although it is tagged as a 'Randomized Controlled Trial' in publication types, this refers to the random split of data for model training/testing, not a trial comparing drug interventions. There is no time-to-event efficacy endpoint (OS, PFS, etc.) and it is not a Phase III or definitive trial report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT). PMID 37777738 · BMC Cancer · 2023-Sep-30 The record is a Phase II randomized trial protocol for radiation therapy in prostate cancer. It lacks Phase III/IIIb status, does not involve a drug-containing intervention, uses toxicity scores (not time-to-event endpoints) as primary outcomes, and has no reported results (only protocol design). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial. PMID 37773134 · Breast Cancer Res · 2023-Sep-29 The record is a secondary, biomarker-focused analysis of a randomized trial. While the trial itself may be a definitive phase, the abstract does not establish the phase, and the analysis is not a primary efficacy report of the trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science (ACCSIS) in Appalachia: protocol for a group randomized, delayed intervention trial. PMID 37202831 · Transl Behav Med · 2023-Sep-28 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. PMID 37752117 · Signal Transduct Target Ther · 2023-Sep-27 The record is a randomized, placebo-controlled trial of a drug combination (FOLFOX4-ATRA) in advanced hepatocellular carcinoma, reporting OS and PFS with hazard ratios. However, the trial phase is not explicitly stated in the title or abstract, and the deterministic review signals that phase evidence is unclear. Without explicit Phase III/IIIb or Phase II/III designation, the record does not meet all required eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. PMID 37752114 · Blood Cancer J · 2023-Sep-27 The record clearly describes an updated report from a randomized Phase 3 drug trial in human oncology. However, the abstract is missing, and no explicit signal for a time-to-event efficacy endpoint (like OS/PFS with KM/HR) is present in the provided title or metadata. Therefore, eligibility cannot be established with certainty. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Locoregional Therapy for Intrahepatic Cholangiocarcinoma: The Role of Intra-Arterial Therapies. PMID 37835420 · Cancers (Basel) · 2023-Sep-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The "home-based exercise for breast and prostate cancer patients during treatment-a feasibility trial" (BENEFIT CA trial): rationale and methodological protocol. PMID 37752564 · Pilot Feasibility Stud · 2023-Sep-26 This is a protocol for a non-randomized, single-arm feasibility study of a home-based exercise intervention for cancer patients. It is not a randomized trial, does not involve a drug intervention, and has no time-to-event efficacy endpoint (the primary outcome is adherence). Therefore, it does not meet any of the core eligibility criteria. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The effects of synbiotics supplementation on reducing chemotherapy-induced side effects in women with breast cancer: a randomized placebo-controlled double-blind clinical trial. PMID 37752516 · BMC Complement Med Ther · 2023-Sep-26 The study is a randomized, double-blind, placebo-controlled trial in breast cancer patients evaluating synbiotics as an adjuvant to chemotherapy. However, it lacks a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary outcome is severity of chemotherapy side effects (fatigue, defecation, nausea, anorexia), which are patient-reported symptoms or quality-of-life measures, not survival or progression endpoints. Phase is not explicitly stated, but even if it were Phase III, the absence of a time-to-event endpoint makes it ineligible for the Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial. PMID 37752423 · BMC Cancer · 2023-Sep-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Endoscopic ultrasonography-guided gastroenterostomy versus surgical gastrojejunostomy for palliation of malignant gastric outlet obstruction (ENDURO): study protocol for a randomized controlled trial. PMID 37749590 · Trials · 2023-Sep-25 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| L-Glutamine and Survival of Patients with Locally Advanced Head and Neck Cancer Receiving Chemoradiotherapy. PMID 37836400 · Nutrients · 2023-Sep-23 The record is an original randomized controlled trial in oncology with human patients, a drug-containing intervention (glutamine as part of supportive care), and time-to-event efficacy endpoints (OS, PFS). However, the trial phase is not explicitly stated in the provided metadata, and the deterministic review indicates phase3_evidence_unclear. Without explicit confirmation of Phase III/IIIb or Phase II/III status, eligibility cannot be established as true. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. PMID 37790413 · Res Sq · 2023-Sep-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Trial Design for Cancer Immunotherapy: A Methodological Toolkit. PMID 37760636 · Cancers (Basel) · 2023-Sep-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Heparanase inhibition leads to improvement in patients with acute gastrointestinal injuries induced by sepsis. PMID 37744293 · World J Gastroenterol · 2023-Sep-21 The study is a randomized controlled trial in human patients, but it investigates sepsis-induced acute gastrointestinal injury, not a malignant neoplasm. The primary outcomes are biomarker levels, clinical scores, and 28-day survival (a mortality endpoint, but not reported as a time-to-event analysis with Kaplan-Meier or HR). The intervention is a drug (low molecular weight heparin), but the study is not oncology. Therefore, it is excluded as non-oncology. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial. PMID 37735634 · BMC Cancer · 2023-Sep-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. PMID 37733309 · N Engl J Med · 2023-Sep-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparing the accuracy of positive and negative indocyanine green staining in guiding laparoscopic anatomical liver resection: protocol for a randomised controlled trial. PMID 37730389 · BMJ Open · 2023-Sep-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer. PMID 37487144 · J Clin Oncol · 2023-Sep-20 The record describes a secondary analysis of two randomized trials (PORTEC-1 and PORTEC-2) focusing on molecular classification as a predictive factor for radiotherapy response. The interventions are non-drug (radiotherapy vs. no therapy or brachytherapy), and the report is not the original primary result report of the trials. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial. PMID 37726695 · BMC Cancer · 2023-Sep-19 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Expanding CYLD protein in NF-κβ/TNF-α signaling pathway in response to Lactobacillus acidophilus in non-metastatic rectal cancer patients. PMID 37725175 · Med Oncol · 2023-Sep-19 The study meets the oncology, human, randomized, time-to-event, and original-result criteria. However, it fails the drug-intervention criterion because the intervention is a probiotic supplement, not a drug or drug-containing regimen. The phase is also not explicitly established as a definitive (Phase III/IIIb or Phase II/III) trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Best analgesia control in pancreatic adenocarcinoma study: justification and feasibility of a randomised trial of early EUS-CPN versus standard care-a prospective observational study (The BAC-PAC study). PMID 39516701 · BJC Rep · 2023-Sep-18 The record describes a prospective observational feasibility study for a planned randomised trial, not a completed randomized trial. It lacks Phase III/IIIb or Phase II/III evidence, a drug intervention, and a primary time-to-event efficacy endpoint for adjudication. It is a protocol/feasibility justification, not a primary result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. PMID 37723577 · Arthritis Res Ther · 2023-Sep-18 The study is not oncology; it is a randomized Phase III trial of upadacitinib for ankylosing spondylitis, a rheumatologic condition, with no time-to-event efficacy endpoints. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Medico-economic impact of thoracoscopy versus thoracotomy in lung cancer: multicentre randomised controlled trial (Lungsco01). PMID 37723516 · BMC Health Serv Res · 2023-Sep-18 Study is a randomized trial in human lung cancer but compares two surgical techniques (video-thoracoscopy vs. thoracotomy) without a drug intervention. The primary and reported outcomes are medico-economic (cost-minimization, cost-utility) and quality-of-life (QALYs), not a standard oncology time-to-event efficacy endpoint (OS, PFS, etc.). Therefore, it does not meet the core criteria for a drug-intervention Kaplan-Meier cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD. PMID 37715270 · Trials · 2023-Sep-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Allocation of authorship and patient enrollment among global clinical trials in oncology. PMID 37382190 · Cancer · 2023-Sep-15 The record is a cross-sectional retrospective cohort study analyzing authorship and patient enrollment patterns among multiple Phase III oncology RCTs, not an original result report of a single trial with a drug intervention and a time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial. PMID 37294085 · Int J Cancer · 2023-Sep-15 The record describes a secondary analysis of a geographic subset (East Asian) of a larger Phase III trial. It is not the original formal report of the primary trial results, which is required for inclusion. The phase of the parent trial (CLEAR) is likely Phase III, but the specific publication analyzes a subset and is therefore classified as a secondary report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN). PMID 36578194 · Gut Liver · 2023-Sep-15 The study is a Phase 3, open-label, single-arm trial of infliximab for intestinal Behçet's disease, which is not a malignant neoplasm. It lacks a randomized design and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or use Kaplan-Meier/HR analysis for such an endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. PMID 39516358 · BJC Rep · 2023-Sep-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Expanded statistical analysis plan for legacy and long-term effects of aspirin in the ASPREE-XT observational follow-up study of participants in the ASPREE randomized trial. PMID 37745426 · medRxiv · 2023-Sep-14 The record describes a statistical analysis plan for a post-trial observational study (ASPREE-XT) following the original ASPREE randomized trial. While the original trial was a randomized Phase III trial of aspirin (a drug) in a non-cancer population, this specific document is a protocol/plan, not a report of formal results with a primary/key secondary time-to-event efficacy endpoint for a human malignant neoplasm. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial). PMID 37710198 · BMC Cancer · 2023-Sep-14 The record describes a protocol for a randomized trial with oncology, human, randomized, and time-to-event criteria met. It includes a drug intervention (tamoxifen). However, it is a protocol (ClinicalTrials.gov ID: NCT04046159) and does not report formal trial results. Additionally, the trial phase is not explicitly stated as Phase III, IIIb, or II/III in the provided metadata, making that criterion unclear. Therefore, it is not eligible as an original formal-result report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Rationale and design of IMPACT-women: a randomised controlled trial of the effect of time-restricted eating, healthy eating and reduced sedentary behaviour on metabolic health during chemotherapy for early-stage breast cancer. PMID 36453589 · Br J Nutr · 2023-Sep-14 This is a protocol for a randomized controlled trial evaluating dietary and lifestyle interventions in breast cancer patients during chemotherapy. It does not meet eligibility because it is a protocol (not a result report), lacks a time-to-event efficacy endpoint, does not confirm a drug-containing intervention (the intervention is non-drug), and is not a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemoradiation therapy combined with immunotherapy for microsatellite stable ultra-low rectal cancer (CHOICE II): study protocol of a multicentre prospective randomised clinical trial. PMID 37709314 · BMJ Open · 2023-Sep-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. PMID 37702300 · Cochrane Database Syst Rev · 2023-Sep-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial. PMID 37700348 · Radiat Oncol · 2023-Sep-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial). PMID 37699634 · BMJ Open · 2023-Sep-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of peer-delivered physical activity promotion and maintenance programs for initially sedentary breast cancer survivors. PMID 37155603 · Transl Behav Med · 2023-Sep-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |